Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report

SIMPLE SUMMARY: Naxitamab (Danyelza®) is a newly FDA-approved humanized anti-GD2 antibody for the treatment of relapsed/refractory in the bone/bone-marrow-only compartment high-risk neuroblastoma. In our center, we had the unique opportunity to use Naxitamab in patients achieving complete remission...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora, Jaume, Castañeda, Alicia, Gorostegui, Maite, Varo, Amalia, Perez-Jaume, Sara, Simao, Margarida, Muñoz, Juan Pablo, Garraus, Moira, Larrosa, Cristina, Salvador, Noelia, Lavarino, Cinzia, Krauel, Lucas, Mañe, Salvador
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177429/
https://www.ncbi.nlm.nih.gov/pubmed/37174002
http://dx.doi.org/10.3390/cancers15092535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177429/
https://www.ncbi.nlm.nih.gov/pubmed/37174002
http://dx.doi.org/10.3390/cancers15092535

Ejemplares similares